Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Jun 22, 2021 10:42am
109 Views
Post# 33426855

NAFLD passed down to children

NAFLD passed down to children

The condition affects patients in any age group.

 

“The risk for the development of disease was also associated with obese fathers. However, the risk was much less in comparison to the obese mothers. Another interesting fact about the prevalence of disease was that the offspring of non-obese mothers also manifested the disease but in much lesser quantity. According to the statistics, 20% of children of non-obese mothers had Non-Alcoholic Fatty Liver.

Being a non-transmissible disease, the transmission of NAFLD from mother to her offspring is quite enchanting. As per Dr. Kushala Abeysekera, Lecturer at the University of Bristol, maternal pre-pregnancy obesity is causing an early life effect to prime the [offsprings’] livers to develop fatty liver, making them vulnerable to environmental hits,” Indicating the effect of the obesogenic environment that can be transferred to generations.

Professor of endocrinology and metabolism at the University of Southampton, Chris Byrne, also highlighted a significant point. Since the children inherit mitochondria from their mother and not from their father, this powerhouse can be involved in this process.”

 

https://www.healthradar360.com/non-alcoholic-fatty-liver-disease-can-pass-down-from-parents-to-children-study/

<< Previous
Bullboard Posts
Next >>